

Reference: FOI.ICB-2223/070

Subject: Primary Care Rebate Schemes

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE			
<p>What primary care rebate schemes does your ICB/ Board currently hold (brand and generic if possible)?</p> <p>What are the start and end dates of the contract? Or is it an ongoing contract?</p>	Product brand name	Generic name/product	Start date	End date
	Adcal D3	colecalciferol	01/04/2018	Until termination
	Apidra	insulin glulisine	01/04/2022	31/03/2023
	BD Viva	Pre-filled insulin Pen needles	Company deems start dates/end dates/term as commercially sensitive	
	Butec	buprenorphine patches	01/04/2021	31/03/2023
	Buvidal	buprenorphine P/R solution for injection	01/07/2021	31/12/2023
	Clenil	CFC-free beclometasone	01/07/2022	30/06/2024
	Clexane	enoxaparin	01/04/2022	31/12/2022
	Dalonev	calcipotriol with betamethasone	01/05/2021	31/03/2023
	Espranor	buprenorphine oral lyophilisate	01/01/2022	31/12/2023
	Fostair NEXThaler	beclometasone dipropionate/formoterol fumarate dihydrate pressurised metered dose	01/07/2022	30/06/2024
	Fostair pMDI	beclometasone dipropionate/formoterol fumarate dihydrate dry powder inhaler	01/07/2022	30/06/2024

FreeStyle Libre	FreeStyle Libre sensor, FreeStyle Libre2 sensor	01/09/2022	31/08/2023
Gatalin XL	galantamine	01/06/2022	31/12/2022
Glucophage	metformin	01/07/2022	30/06/2024
Insuman	isophane insulin	01/04/2022	31/03/2023
Longtec	oxycodone SR	01/10/2021	Until termination
NovoRapid	pre-filled insulin pen cartridge	01/08/2021	31/07/2023
Onglyza	saxagliptin	Roll on of pre-merge agreements	Until termination
Pipexus	pramipexole PR tablets	01/11/2019	Until termination
Prostap	leuprorelin DCS (&DCS SR)	Company deems start dates/end dates/term as commercially sensitive	
Solaraze	diclofenac gel sodium 3%	01/12/2021	30/11/2022
Stexerol	colecalfiferol	01/10/2018	Until termination
Strivit	colecalfiferol	01/04/2021	31/03/2024
Vizidor & Vizidor Duo	dorzolamide hydrochloride/dorzolamide hydrochloride timolol maleate	01/01/2022	31/12/2023
Xaggitin	methylphenidate	01/04/2018	Until termination
Zacco	clobazam Oral Suspension	01/07/2022	30/09/2023
Zaluron XL	quetiapine	01/04/2018	31/03/2023

The ICB has applied Section 43(2) to the start and end dates of the rebate schemes for BD Viva and Prostap.

Section 43(2) exempts from disclosure information which would, or would be likely to, prejudice the commercial interests of an organisation. The contracts relating to BD Viva and Prostag include a clause which outlines the start date, end date and term as commercially sensitive. The contract holder has confirmed that the information is considered commercially sensitive and provided their reasoning. The ICB has considered this information when applying the public interest test to the exemption.

The public interest arguments in favour of disclosing information include the ICB's responsibility to be transparent and accountable in its decision making. The ICB policy for Sponsorship of Activities by and Joint Working with the Pharmaceutical Industry outlines the values the ICB adheres to when working with the pharmaceutical industry and this includes the principle for the ICB to promote confidence between staff, patients and the public through transparency of NHS activities. The policy also outlines that information relating to rebate schemes is disclosable under the FOI Act and only information considered commercially sensitive should be redacted.

The public interest arguments in favour of maintaining the exemption include the contract clause noting the information as commercially sensitive and the subsequent confirmation of this from the contract holder and their reasoning for why they consider the information

	<p>commercially sensitive. Rebate schemes allow organisations to offer a financial rebate to the ICB and these schemes are considered on clinical, financial and contractual grounds and will only be considered if the medicines are appropriate and of value to the ICB population. The ICB has considered that disclosure of the information may lead to the contract holder not offering this type of scheme again which may result in the ICB having to spend more public funds on prescribing. The ICB has a responsibility to secure the best use of public resources and provide value for money.</p> <p>The ICB has considered the balance of both disclosing the information and maintaining the exemption and believes that it is in the public's best interest to apply the exemption. The ability for organisations to offer rebate schemes to the ICB reduces the amount of public funding used for prescribing and allows for the more effective use of resources to ensure that the ICB achieves value for money.</p>
--	---

The information provided in this response is accurate as of 14 October 2022 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.